Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALPHAMAB-B

9.960
-0.100-0.99%
Volume:1.73M
Turnover:17.26M
Market Cap:9.66B
PE:52.60
High:10.150
Open:9.850
Low:9.580
Close:10.060
52wk High:15.750
52wk Low:3.050
Shares:970.00M
HK Float Shares:970.00M
Volume Ratio:0.89
T/O Rate:0.18%
Dividend:- -
Dividend Rate:- -
EPS(LYR):0.189
ROE:13.37%
ROA:5.22%
PB:4.75
PE(LYR):52.60
PS:11.22

Loading ...

Alphamab Oncology files next day disclosure return to HKEX announcing repurchase of 293000 shares at HKD 135389 per share

Reuters
·
Oct 14

ALPHAMAB-B (09966) Repurchases 293,000 Shares for HK$3.97 Million on October 14

Stock News
·
Oct 14

Alphamab Oncology files next day disclosure return to HKEX announcing repurchase of 108000 shares at HKD 137589 per share

Reuters
·
Oct 13

BRIEF-Alphamab Oncology To Repurchase Shares Up To HK$20 Million

Reuters
·
Oct 13

ALPHAMAB-B (09966) Plans On-Market Share Buyback

Stock News
·
Oct 13

Alphamab Oncology - to Repurchase Shares up to HK$20 Mln

THOMSON REUTERS
·
Oct 13

Biotech Stocks Jump. Immunotech up 17%; Carsgen up 14%; BRII up 6%; JW Therap up 4%; Sirnaomics up 3%

Tiger Newspress
·
Oct 06

HK Movers|Biotech Stocks Rose. Laekna Up 14%; RemeGen Rose 3%; Microport Up 2%; JW Therap, Zai Lab And Lepu Up 1%

Tiger Newspress
·
Sep 29

Undiscovered Gems in Asia for September 2025

Simply Wall St.
·
Sep 24

Hong Kong Stock Movement | ALPHAMAB-B (09966) Surges Over 4% After KN026 New Drug Application Accepted by National Medical Products Administration

Stock News
·
Sep 23

Alphamab Oncology's Director Reports Listing Rule Breach with Spouse's Share Sale; Shares Up 4%

MT Newswires Live
·
Sep 22

Alphamab Oncology (HKG:9966) Shares Fly 35% But Investors Aren't Buying For Growth

Simply Wall St.
·
Sep 13

BUZZ-Alphamab hits 22-month peak as regulator accepts cancer drug application

Reuters
·
Sep 12

Biotech Stocks Rebound. Transthera up 16%; Hightide up 13%; Clover Bio up over 9%; Alphamab up 8%; Zai Lab, Jacobio up over 6%; Mirxes up 5%

Tiger Newspress
·
Sep 12

BRIEF-Alphamab Oncology Says NDA For KN026 Accepted By NMPA

Reuters
·
Sep 11

ALPHAMAB-B (09966): New Drug Application for KN026 (Annytuzumab Injection) Accepted by China's NMPA

Stock News
·
Sep 11

Alphamab Oncology's KN026 NDA for HER2+ Gastric Cancer Accepted by China's NMPA, Achieving Breakthrough Therapy Designation and Priority Review Status

Reuters
·
Sep 11

Alphamab Oncology - Nda for Kn026 Accepted by Nmpa

THOMSON REUTERS
·
Sep 11

HK Movers | Biotech Stocks Plunge. Ascletis Pharma down 14%; Clover Bio, Transcenta down over 10%; Beigene, HBM Holdings down over 8%; Jacobio down over 7%

Tiger Newspress
·
Sep 11

Alphamab Oncology (SEHK:9966) Reports Revenues Of CNY 319 Million For Half Year Ending June 2025

Simply Wall St.
·
Sep 11